Risk factors for esophago-jejunal anastomosis leakage after total gastrectomy for cancer. A multicenter retrospective study of the Italian research group for gastric cancer.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
12 2020
Historique:
received: 30 04 2020
revised: 25 05 2020
accepted: 18 06 2020
pubmed: 25 7 2020
medline: 2 3 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

Many Eastern reports attempted to identify predictive variables for esophago-jejunal anastomosis leakage (EJAL) after total gastrectomy for cancer. There are no definitive answers about reliable risk factors for EJAL. This retrospective study shows the largest Western series focused on this topic. This is a multicenter retrospective study analyzing patients' datasets collected by 18 Italian referral Centres of the Italian Research Group for Gastric Cancer (GIRCG) from 2000 to 2018. The inclusion criteria were pathological diagnosis of gastric and esophageal (Siewert III) carcinoma requiring total gastrectomy. The primary end point of risk analysis was the occurrence of EJAL; secondary end points were post-operative (30-day) morbidity and mortality, length of stay (LoS), and survival. Data of 1750 patients submitted to total gastrectomy were collected. EJAL developed in 116 (6.6%) patients and represented the 26.3% of all the 441 observed post-operative surgical complications. EJAL diagnosis was followed by a reoperation in 39 (33.6%) patients and by an endoscopic/radiological procedure in 30 cases (25.9%). In 47 patients (40.5%) EJAL was managed with conservative approach. Post-operative LoS and mortality were significantly higher after EJAL occurrence (27 days versus 12 days and 8.6% versus 1.6%, respectively). At risk analysis, comorbidities (particularly, if respiratory), minimally invasive surgery, extended lymphadenectomy, and anastomotic technique resulted significant predictive factors for EJAL. EJAL did not significantly affect survival. These results were consistent with Asian experiences: the frequency of EJAL and its higher rate observed in patients with comorbidities or after minimally invasive approach were confirmed.

Sections du résumé

BACKGROUND
Many Eastern reports attempted to identify predictive variables for esophago-jejunal anastomosis leakage (EJAL) after total gastrectomy for cancer. There are no definitive answers about reliable risk factors for EJAL. This retrospective study shows the largest Western series focused on this topic.
METHODS
This is a multicenter retrospective study analyzing patients' datasets collected by 18 Italian referral Centres of the Italian Research Group for Gastric Cancer (GIRCG) from 2000 to 2018. The inclusion criteria were pathological diagnosis of gastric and esophageal (Siewert III) carcinoma requiring total gastrectomy. The primary end point of risk analysis was the occurrence of EJAL; secondary end points were post-operative (30-day) morbidity and mortality, length of stay (LoS), and survival.
RESULTS
Data of 1750 patients submitted to total gastrectomy were collected. EJAL developed in 116 (6.6%) patients and represented the 26.3% of all the 441 observed post-operative surgical complications. EJAL diagnosis was followed by a reoperation in 39 (33.6%) patients and by an endoscopic/radiological procedure in 30 cases (25.9%). In 47 patients (40.5%) EJAL was managed with conservative approach. Post-operative LoS and mortality were significantly higher after EJAL occurrence (27 days versus 12 days and 8.6% versus 1.6%, respectively). At risk analysis, comorbidities (particularly, if respiratory), minimally invasive surgery, extended lymphadenectomy, and anastomotic technique resulted significant predictive factors for EJAL. EJAL did not significantly affect survival.
CONCLUSIONS
These results were consistent with Asian experiences: the frequency of EJAL and its higher rate observed in patients with comorbidities or after minimally invasive approach were confirmed.

Identifiants

pubmed: 32703713
pii: S0748-7983(20)30560-6
doi: 10.1016/j.ejso.2020.06.035
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2243-2247

Investigateurs

Maria Bencivenga (M)
Mariagiulia Dal Cero (M)
Fausto Rosa (F)
Sergio Alfieri (S)
Guido Alberto Tiberio (GA)
Marie Sophie Alfano (MS)
Monica Gualtierotti (M)
Giovanni Ferrari (G)
Roberto Persiani (R)
Alberto Biondi (A)
Annibale Donini (A)
Luigina Graziosi (L)
Diego Sasia (D)
Paolo Geretto (P)
Jacopo Vigano (J)
Enrico Cicuttin (E)
Federica Galli (F)
Paolo Strignano (P)
Elena Mazza (E)
Antonio Taddei (A)
Ilenia Bartolini (I)
Lucio Taglietti (L)
Silvia Ruggiero (S)
Elio Treppiedi (E)
Vittorio Postiglione (V)
Francesco Casella (F)
Andrea Sansonetti (A)
Carlo Abatini (C)
Miriam Attalla El Halabieh (M)
Paolo Millo (P)
Antonella Usai (A)
Michela Mineccia (M)
Alessandro Ferrero (A)

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Renza Trapani (R)

Surgical Oncology and Digestive Surgery Unit, Department of Oncology of San Luigi University Hospital of Orbassano, Orbassano, Turin, Italy. Electronic address: renza.trapani@gmail.com.

Stefano Rausei (S)

Department of Surgery, ASST Valle Olona, Gallarate, Varese, Italy. Electronic address: stefano.rausei@gmail.com.

Rossella Reddavid (R)

Surgical Oncology and Digestive Surgery Unit, Department of Oncology of San Luigi University Hospital of Orbassano, Orbassano, Turin, Italy. Electronic address: rossella.reddavid@gmail.com.

Maurizio Degiuli (M)

Surgical Oncology and Digestive Surgery Unit, Department of Oncology of San Luigi University Hospital of Orbassano, Orbassano, Turin, Italy. Electronic address: maurizio.degiuli@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH